Default company panoramic image
Logo

NanoRods, LLC

Offering proven patented solution for until-now-unresolved challenges in painless surgery-free treatment of neck and advanced skin cancers.

  • Stage Prototype Ready
  • Industry Nanotechnology
  • Location Rockville, MD, USA
  • Currency USD
  • Founded May 2008
  • Employees 5
  • Website goldnrs.com

Company Summary

A cancer diagnosis brings fear of death and collateral damage. Surgery, chemotherapy and radiation are invasive with undesirable side effects. Our proprietary device technology has overcome until-now-unresolved, technical and large scale fabrication challenges. In partnership with our customer, Siva Therapeutics, our patented bio-functionalized gold nanorods will be used as a new approach for some cancer and rheumatoid arthritis treatments.

Team

  • Default avatar
    Dr. Babak Nikoobakht
    Chief Executive Officer

    The work of NanoRods founder and CTO is well known, with more than 3200 scientific citations. He has led the successful mass production and sale of bio-conjugated gold nanorods. NanoRods has already issued an exclusive license to Siva Therapeutics. He is also leading the efforts in working with potential customers including United Tech Corporation, General Electric and Rockwell Collins as well as distributor like Ted Pella, Inc, and Alfa Aesar.

  • Default avatar
    Michael V Akbar
    Senior VP Sales & Marketing

    Former President of Syntony has extensive experience with start-up, maturity and growth business environments, a unique blend of sales, marketing and ops experience in Manufacturing, Technology and Services sectors. With 30 years in business, including 10 years with IBM and GE, he has demonstrated strong people, process, and leadership skills offering strategic and tactical leadership during significant transition and growth business cycles.

  • Default avatar
    Dr. Jiguang Li
    The principal investigator

    Dr. Li has an extensive experience in nanotechnology research, including surface functionalization and thin film polymer coating; prior to joining NanoRods, he collaborated with one of the leading figures in chemistry, Alan Heeger, the 2000 Noble prize winner.

  • Default avatar
    Javier Goldin
    Chief Financial Officer

    Mr. Goldin is the former Chief of Accounting, Reporting and Financial Policy at the Organization of American States and a Managing Partner at Goldin Group LLC. As the outsourced Chief Financial Officer, Mr. Goldin’s responsibility at NanoRods is Financial Strategy and oversight.

  • Default avatar
    Vacant TBD
    Operations Manager

    NanoRods is in the process of finalizing its selection for an operations manager who will be responsible for the oversight of all operational and non-scientific functions. These functions include but not limited to book keeping, administrative support and co-ordination with HR and Benefits, IT support, NanoRods accounting firm, Insurance, and Federal, State, and Local governments.

  • Default avatar
    Dr. Lawrence Tamarkin
    Chair Advisory Board

    As CEO and Founder he has lead CytImmune since 1988. He is the co-inventor of the colloidal gold-based, tumortargeted nanomedicine platform technology, covered in 49 allowed and 42 pending patents. The Company’s first cancer nanomedicine, Aurimune, has been successfully tested in a Phase I advanced-stage cancer patient study, and Phase II testing in combination with approved chemotherapies is planned for Q3 2013.

  • Default avatar
    Dr. Len Pagliaro
    Senior Member Advisory Board

    CEO of Siva Therapeutics has 16 years of experience with commercialization of biotechnology products, services, and licensing, following an academic career as a professor of Bioengineering and Laboratory Medicine at the University of Washington. He managed R&D and P&L for a business unit of Thermo Fisher Scientific selling tools for drug discovery. He has led molecule oncology projects. He is responsible for overall corporate strategy at Siva.

Advisors

  • Default avatar
    SteinMcEwen LLP
    Lawyer
    Unconfirmed
    Default avatar
    Javier Goldin
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Previous sources of funding:
    Unconfirmed
    Default avatar
    Maryland Technology Corporation (TEDCO) , NSF SBIR, DARPA
    Unconfirmed
    Default avatar
    Air Force STTR, Siva Therapeutics and GE
    Unconfirmed